Photosensitive epilepsy

disease
On this page

Also known as photoparoxysmal responsePSE

Summary

Photosensitive epilepsy (MONDO:0015643) is a disease and 11 clinical trials. Top therapeutic interventions include carbamazepine, fenfluramine hydrochloride, and lactulose. A subtype of inherited reflex epilepsy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: 1-5 / 10 000 (Worldwide) [Orphanet-validated]
  • Clinical trials: 11

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Point prevalence1-5 / 10 00030WorldwideValidated

Identifiers

Disease identifiers

FieldValue
Canonical namephotosensitive epilepsy
Mondo IDMONDO:0015643
OMIM132100
Orphanet166409
DOIDDOID:0060281
ICD-11946957931
SNOMED CT95208000
UMLSC0393720
MedGen98285
GARD0005648
Is cancer (heuristic)no

Also known as: photoparoxysmal response · PSE

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › nervous system disordercentral nervous system disorderbrain disorderepilepsy › reflex epilepsy › inherited reflex epilepsy › photosensitive epilepsy

Related subtypes (1): hot water reflex epilepsy

Subtypes (4): photoparoxysmal response 1, photoparoxysmal response 2, photoparoxysmal response 3, Sunflower syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE26
PHASE41
PHASE2/PHASE31
PHASE31
PHASE11
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00609245PHASE4COMPLETEDEffect of Valproic Acid Concentration on Photic Response
NCT03580707PHASE2/PHASE3COMPLETEDDoes BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint
NCT03790137PHASE3COMPLETEDTreatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
NCT00579384PHASE2COMPLETEDA Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy
NCT00784212PHASE2COMPLETEDEffect of BGG492 on EEG in Patients With Photosensitive Epilepsy
NCT00894010PHASE2COMPLETEDPhotosensitivity Proof of Concept Trial
NCT03239691PHASE2COMPLETEDA Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients
NCT03603639PHASE2TERMINATEDA Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy
NCT03686033PHASE2TERMINATEDA Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy
NCT06525649PHASE1COMPLETEDA Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042
NCT01283152Not specifiedCOMPLETEDEfficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CARBAMAZEPINE41
FENFLURAMINE HYDROCHLORIDE41
LACTULOSE41
VALPROIC ACID41
POLYETHYLENE GLYCOL31
JNJ-2648911221
SELURAMPANEL21